The price of Transmedics Group Inc (NASDAQ: TMDX) closed at $77.74 in the last session, down -6.50% from day before closing price of $83.14. In other words, the price has decreased by -$5.40 from its previous closing price. On the day, 2652846 shares were traded. TMDX stock price reached its highest trading level at $82.00 during the session, while it also had its lowest trading level at $72.08.
Ratios:
We take a closer look at TMDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.13 and its Current Ratio is at 10.93. In the meantime, Its Debt-to-Equity ratio is 4.08 whereas as Long-Term Debt/Eq ratio is at 4.06.
On August 02, 2022, JP Morgan Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $48.
JP Morgan Downgraded its Overweight to Neutral on October 08, 2020, while the target price for the stock was maintained at $15.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 20 when Khayal Tamer I sold 250 shares for $90.00 per share. The transaction valued at 22,500 led to the insider holds 14,375 shares of the business.
Khayal Tamer I sold 2,858 shares of TMDX for $257,220 on Feb 16. The Chief Commercial Officer now owns 14,375 shares after completing the transaction at $90.00 per share. On Feb 15, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 776 shares for $90.00 each. As a result, the insider received 69,840 and left with 14,375 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 2.54B and an Enterprise Value of 2.80B. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.23 while its Price-to-Book (P/B) ratio in mrq is 20.07. Its current Enterprise Value per Revenue stands at 14.61 whereas that against EBITDA is -113.29.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $99.63, while it has fallen to a 52-week low of $36.42. The 50-Day Moving Average of the stock is 82.87, while the 200-Day Moving Average is calculated to be 71.64.
Shares Statistics:
According to the various share statistics, TMDX traded on average about 449.82K shares per day over the past 3-months and 484.27k shares per day over the past 10 days. A total of 32.14M shares are outstanding, with a floating share count of 31.46M. Insiders hold about 3.63% of the company’s shares, while institutions hold 109.21% stake in the company. Shares short for TMDX as of Jan 31, 2024 were 5.42M with a Short Ratio of 12.06, compared to 5.58M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 16.62% and a Short% of Float of 19.23%.
Earnings Estimates
The company has 4 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.03 for the current quarter, with a high estimate of $0.08 and a low estimate of -$0.08, while EPS last year was -$0.21. The consensus estimate for the next quarter is -$0.23, with high estimates of $0.09 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$0.76 and -$1.02 for the fiscal current year, implying an average EPS of -$0.93. EPS for the following year is -$1.26, with 3 analysts recommending between -$0.65 and -$2.27.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $68.51M. It ranges from a high estimate of $70.4M to a low estimate of $67.1M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $31.38M, an estimated increase of 118.40% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $74.66M, an increase of 79.70% less than the figure of $118.40% in the same quarter last year. There is a high estimate of $77.8M for the next quarter, whereas the lowest estimate is $71.83M.
A total of 6 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $230.8M, while the lowest revenue estimate was $226M, resulting in an average revenue estimate of $228.46M. In the same quarter a year ago, actual revenue was $93.46M, up 144.40% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $330.23M in the next fiscal year. The high estimate is $371.2M and the low estimate is $299.98M. The average revenue growth estimate for next year is up 44.50% from the average revenue estimate for this year.
